Monoclonal Antibody Targeting of Anti-Cancer Agents

  • R. W. Baldwin
Part of the NATO ASI Series book series (NSSA, volume 120)


The concept of targeting cytotoxic agents to tumour sites following linkage to antibodies has become more acceptable following the development of monoclonal antibodies which react with tumour associated antigens (1). These include anti-CEA monoclonal antibodies in colorectal cancer as well as antibodies designated 791T/36, 19–9 and 17–1A, which react with colon carcinoma-associated membrane antigens. Monoclonal antibodies have also been produced which react with other types of human cancer including malignant melanoma, bone and soft tissue sarcomas, and carcinomas of breast, ovary and lung (1).


Osteogenic Sarcoma Colon Carcinoma Metastatic Tumour Antibody Conjugate Cancer Research Campaign 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    R. W. Baldwin, and V. S. Byers, “Monoclonal Antibodies for Tumour Detection and Drug Targeting”, Academic Press, 1985.Google Scholar
  2. 2.
    J. W. Uhr, Immunotoxins: Harnessing Nature’s Poisons. J. Immunol. 133: 1 (1984).Google Scholar
  3. 3.
    R. W. Baldwin, Design and development of drug-monoclonal antibody 791T/36 tor cancer therapy, in: “Monoclonal Antibody Therapy of Human Cancer”, K. Foon, and A. C. Morgan, eds., Martinus Nijhoff, Boston, p. 23–56 (1985).Google Scholar
  4. 4.
    G. F. Rowland, and R. G. Simmonds, Effects of monoclonal antibody-drug conjugates on human tumour cell cultures and xenografts, in: “Monoclonal Antibodies for Tumour Detection and Drug Targeting”, R. W. Baldwin, and V. S. Byers, eds., Academic Press, (1985).Google Scholar
  5. 5.
    J. M. Pelham, J. Dixon-Gray, G. R. Flannery, M. V Pimm, and R.W. Baldwin, Interferon conjugation to human osteogenic sarcoma monoclonal antibody 791T/36. Cancer Immunol. Immunother. 15: 210 (1983).PubMedCrossRefGoogle Scholar
  6. 6.
    M. J. Embleton, B. Gunn, V. S. Byers, and R.W. Baldwin, Antitumour reactions of monoclonal antibody against a human osteogenic sarcoma cell line, Br. J. Cancer, 43: 582 (1981).PubMedCrossRefGoogle Scholar
  7. 7.
    N. C. Armitage, A. C. Perkins, M. V. Pimm, P. A. Farrands, R. W. Baldwin, and J. D. Hardcastle, The localisation of an anti-tumour monoclonal antibody (791T/36) in gastrointestinal tumours. Br. J. Surg. 71: 407 (1984).PubMedCrossRefGoogle Scholar
  8. 8.
    N. C. Armitage, A. C. Perkins, J. D. Hardcastle, M. V. Pimm, and R. W. Baldwin, Monoclonal antibody imaging in malignant and benign gastrointestinal diseases, in: “Monoclonal Antibodies for Tumour Detection and Drug Targeting”, R. W. Baldwin, and V. S. Byers, eds., Academic Press (1985).Google Scholar
  9. 9.
    N. C. Armitage, A. C. Perkins, M. V. Pimm, R. W. Baldwin, and J.D. Hardcastle,11Imaging of primary and metastatic colorectal cancer using an In-labelled antitumour monoclonal antibody (791T/ 36). Nucl. Med. Comm., In press (1985).Google Scholar
  10. 10.
    L. G. Durrant, R. A. Robins, N. C. Armitage, A. Brown, R.W. Baldwin, J. D. Hardcastle, Association of antigen expression and DNA ploidy in colorectal tumours, Cancer Res., In press (1985).Google Scholar
  11. 11.
    K. C. Ballantyne, L. G. Durrant, N. C. Armitage, R. A. Robins, R.W. Baldwin, and J. D. Hardcastle, Monoclonal antibody binding to primary and metastatic colorectal cancer, Gut, 26:Abstr. 1154 (1985).Google Scholar
  12. 12.
    R. W. Baldwin, M. J. Embleton, J. Gallego, M. Garnett, M.W. Pimm, and M.R. Price, Monoclonal antibody drug conjugates for cancer therapy, in: “Monoclonal Antibodies for Diagnosis and Therapy of Cancer”, J. Roth, ed., Futura Publishing Co. (1986).Google Scholar
  13. 13.
    M. C. Garnett, M. J. Embleton, E. Jacobs, and R. W. Baldwin, Preparation and properties of a drug-carrier-antibody conjugate showing selective antibody-directed cytotoxicity in vitro, Int. J. Cancer. 31: 661 (1983).PubMedCrossRefGoogle Scholar
  14. 14.
    M.C. Garnett, and R. W. Baldwin, An improved synthesis of a methotrexate-albumin-791T/36 monoclonal antibody conjugate cytotoxic to osteogenic sarcoma cell lines, Cancer Res., In Press (1986).Google Scholar
  15. 15.
    G. F. Rowland, C. A. Axton, R. W. Baldwin, J. P. Brown, J. R. F. Corvalan, M. J. Embleton, V. A. Gore, I. Hellstrom, K. E. Hellstrom, E. Jacbos, C. H. Marsden, M. V. Pimm, R. G. Simmonds, and W. Smith, Anti-tumour properties of vindesin-monoclonal antibody conjugates, Cancer Immunol. Immunother. 19: 1 (1985).PubMedCrossRefGoogle Scholar
  16. 16.
    J. Gallego, M. R. Price, and R. W. Baldwin, Preparation of tour daunomycin-monoclonal antibody 791T/36 conjugates with anti-tumour activty, Int. J. Cancer. 33: 737 (1984).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1986

Authors and Affiliations

  • R. W. Baldwin
    • 1
  1. 1.Cancer Research Campaign LaboratoriesUniversity of NottinghamNottinghamUK

Personalised recommendations